Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Data from 47,768 cancer survivors and ...
Despite significant health disparities experienced by people with disabilities, their needs are poorly addressed and understood in health policy, research, and practice. Estimates of prevalence vary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results